About: Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $17.39 (+8.28%)
REPL NASDAQ Replimune Group Inc
Replimune Group Inc share price
Atividade de preço de REPL
Último preço
$ 17,390
Variação (24h)
1,33 USD (8,28%)
Volume
5.14M
Volume (média 4 sem.)
-
Abertura
$ 16,27
Variação do dia
$ 16,20 - $ 17,78
Fechamento anterior
$ 16,06
Último negócio
29 Oct, 8:05 pm GMT+0
Atrasado
29 Oct, 8:05 pm GMT+0
REPL price performance
Atrasado
29 Oct, 8:05 pm GMT+0
quote.marketSignals